Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

BioNTech to Acquire CureVac for $1.25 Billion

Backed by the German state bank KfW, the acquisition will boost mRNA-based cancer research despite lingering patent disputes.

BioNTech.
Image
couple de chercheurs Özlem Türeci et Uğur Şahin, co-fondateurs de la start-up BioNTech, lors d'une remise de prix le 10 juin 2025 à Berlin
Logos des deux laboratoires allemands CureVac et BioNTech

Overview

  • BioNTech announced it will acquire CureVac for $1.25 billion to strengthen its mRNA-based oncology and immunotherapy portfolio.
  • CureVac shareholders will receive BioNTech shares valued at a 55% premium on the average stock price over the past three months.
  • The deal, approved by both companies’ boards, is subject to regulatory clearances and is expected to close by the end of 2025.
  • Germany’s KfW public bank, which owns 13.3% of CureVac, and shareholders holding over one-third of the company have committed to the sale despite an ongoing 2022 patent lawsuit between the firms.
  • BioNTech has launched an up to $11.1 billion collaboration with Bristol Myers Squibb to develop a new cancer antibody as competitors such as Moderna and Merck advance their own mRNA oncology pipelines.